Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer... by Michael Simon, Qin Liu, Lawrence Flaherty, Lawrence G. Lum, Archana Thakur, Abhinav Deol, Kristie Fields, Dana Schalk, Zaid Al-Kadhimi, Vidya Kondadasula, Elyse Tomashewski, Patricia Steele, Melissa Giroux

Get full text